RNA P&L Curve

Atrium Therapeutics, Inc. (RNA) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $128.5M, listed on NASDAQ, employing roughly 511 people, carrying a beta of 0.37 to the broader market. Atrium Therapeutics, Inc. Led by Kathleen Gallagher, public since 2026-02-27.

A profit/loss curve charts the theoretical gain or loss of an options position across a range of underlying prices. It helps traders visualize risk, identify breakeven points, and compare strategies before committing capital.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Market Cap
$128.5M
Employees
511
IPO Date
2026-02-27
CEO
Kathleen Gallagher
Beta
0.37

As of Nov 13, 2026, the Atrium Therapeutics, Inc. spot price is $7.66; P&L scenarios can be constructed from the options chain. Payoff diagrams should be rebuilt from the live options chain; the preceding values are illustrative and assume a single at-the-money straddle for reference.